These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12713527)

  • 1. Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists.
    Albanese A; Colosimo C
    Acta Neurol Scand; 2003 May; 107(5):349-55. PubMed ID: 12713527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DA agonists -- ergot derivatives: dihydroergocryptine (DHEC): management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S72-3. PubMed ID: 12211143
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?
    Rascol O
    J Neural Transm Suppl; 1999; 55():33-45. PubMed ID: 10335491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease.
    Calne DB
    J Neural Transm Suppl; 1999; 56():185-92. PubMed ID: 10370912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydroergocryptine in the treatment of Parkinson's disease.
    Bonuccelli U; D'Antonio P; D'Avino C; Piccini P; Muratorio A
    J Neural Transm Suppl; 1995; 45():239-45. PubMed ID: 8748631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum.
    Gerlach M; Double K; Arzberger T; Leblhuber F; Tatschner T; Riederer P
    J Neural Transm (Vienna); 2003 Oct; 110(10):1119-27. PubMed ID: 14523624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
    Bonuccelli U; Del Dotto P; Rascol O
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical studies of pramipexole: clinical relevance.
    Hubble JP
    Eur J Neurol; 2000 May; 7 Suppl 1():15-20. PubMed ID: 11054154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evidence-based review of dopamine receptor agonists in the treatment of Parkinson's disease.
    Deleu D; Northway MG; Hanssens Y
    Saudi Med J; 2002 Oct; 23(10):1165-75. PubMed ID: 12436117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature.
    Thobois S
    Clin Ther; 2006 Jan; 28(1):1-12. PubMed ID: 16490575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the dopamine agonist alpha-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease.
    Minea D; Varga I; Falup-Pecurariu C; de Mey C; Retzow A; Althaus M
    Clin Neuropharmacol; 2001; 24(4):235-8. PubMed ID: 11479396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
    Paus S; Brecht HM; Köster J; Seeger G; Klockgether T; Wüllner U
    Mov Disord; 2003 Jun; 18(6):659-67. PubMed ID: 12784269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.